Neuren Pharmaceuticals Limited (NURPF) Receives a Buy from Ord Minnett
Bell Potter Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
NEU: Revenue up 8% and interim dividend declared, but net profit down 68% on higher R&D costs